Results 101 to 110 of about 24,744 (229)

Efficacy and Safety of Intensifying Once‐Weekly Insulin Icodec Treatment With Once‐Weekly Semaglutide in Adults With Type 2 Diabetes: A Single‐Arm, Open‐Label, Treat‐to‐Target, Phase 3b Trial (ONWARDS 8)

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8515-8522, September 2026.
ABSTRACT Aims To investigate the efficacy and safety of intensifying once‐weekly insulin icodec (icodec) with once‐weekly semaglutide in adults with type 2 diabetes (T2D). Materials and Methods ONWARDS 8 was a single‐arm, open‐label, treat‐to‐target, Phase 3b trial comprising a 26‐week icodec run‐in period and a 26‐week semaglutide intensification ...
Krzysztof Strojek   +5 more
wiley   +1 more source

Kinetic Compatibility as a Predictor of PTP1B Inhibitor Combination Outcomes: An Integrated Experimental and Computational Study

open access: yesChemMedChem, Volume 21, Issue 16, 27 August 2026.
Combining PTP1B inhibitors of distinct kinetic mechanisms determines their pharmacological outcome. Integrating enzyme kinetics, docking, molecular dynamics, and membrane‐permeability simulations, we show that mechanistically compatible pairs (competitive + competitive; uncompetitive + mixed) yield additivity, whereas competitive + uncompetitive ...
Jonathan Trapala   +7 more
wiley   +1 more source

Exploring Disulfide Bridge as a Tool to Improve Pioglitazone’s Neuroprotective Potential: Toward the Development of Prolonged‐Acting MAO‐B/PPARγ Modulators

open access: yesChemMedChem, Volume 21, Issue 15, 14 August 2026.
Pioglitazone is an antidiabetic drug acting as a peroxisome proliferator‐activated receptor γ (PPARγ) agonist and later repositioned as a monoamine oxidase B (MAO‐B) inhibitor. Despite promising preclinical premises, it showed a lack of efficacy in clinical trials as a treatment for neurodegenerative diseases.
Filippo Basagni   +12 more
wiley   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2741-2755, August 2026.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le   +5 more
wiley   +1 more source

Celtis africana (N. L. Burm.) Modulates Glucose Homeostasis and Mitigates Cardiac Tissue Oxidative Injury: Insights From an Ex Vivo Study

open access: yesChemistry &Biodiversity, Volume 23, Issue 8, August 2026.
Celtis africana leaves extracted with different solvents are subjected to chemical analysis, and the metabolites detected dock with lipid and carbohydrate digestive enzymes. The extracts are also tested for modulation of glucose uptake and absorption in the muscles, liver, and intestine, with further evaluation of their in vitro antioxidant bioactivity.
Brian K. Beseni   +4 more
wiley   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 357-374, August 2026.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel   +3 more
wiley   +1 more source

Effects of ketogenic and low‐carbohydrate diet on glucose and weight control in type 2 diabetes mellitus patients along with metabolome change

open access: yesClinical and Translational Discovery, Volume 6, Issue 4, August 2026.
Both the low‐carbohydrate diet (LCD) and the ketogenic diet (KD) positively affect body weight and glucose metabolism in type 2 diabetes. Metabolomic signatures sensitively reflect each diet and correlate with clinical improvements – distinct metabolite associations with glycated haemoglobin and weight were identified for LCD versus KD.
Yao Wang   +11 more
wiley   +1 more source

Integrative GC–MS, FT‐IR, and Molecular Docking Analysis of Drimycarpus racemosus (Roxb.) Hook.f ex Marchand: In Vivo Analgesic and Antidiabetic Potential

open access: yesFood Science &Nutrition, Volume 14, Issue 8, August 2026.
GC–MS profiling of D. racemosus identified bioactive phytochemicals with promising molecular interactions through docking analysis. The methanolic extract demonstrated significant antinociceptive activity against acetic acid‐ and formalin‐induced pain and exhibited antidiabetic effects in streptozotocin‐induced diabetic Swiss albino mice, supporting ...
Md Sajib Ali   +7 more
wiley   +1 more source

Comparative Evaluation of the Antihyperglycemic Potential of Coccinia cordifolia and Gynura procumbens Leaf Extracts: Integrated Phytochemical, In Vivo, Molecular Docking, and DFT Investigations

open access: yesFood Science &Nutrition, Volume 14, Issue 8, August 2026.
Graphical abstract illustrating the overall experimental workflow and antidiabetic evaluation of Coccinia cordifolia and Gynura procumbens extracts. Plant materials were extracted and subsequently investigated through in vivo antidiabetic studies, density functional theory (DFT) analysis, and in silico molecular docking to identify potential bioactive ...
A. J. M. Morshed   +8 more
wiley   +1 more source

Real‐World Effectiveness and Safety of iGlarLixi in People With Type 2 Diabetes in LATAM Region: A Subanalysis of the SUCCESS Study

open access: yes
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8724-8728, September 2026.
Juan Manuel Arteaga‐Diaz   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy